Condition: Hematologic Malignancy · Bone Marrow Transplant Rejection · Acute Myeloid Leukemia (AML) · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patients to proceed with allogeneic peripheral blood transplant (alloBMT). Those being asked to participate have high DSA levels that puts those being asked to participate at high risk of rejecting the available donor's blood stem cells and making those being asked to participate ineligible to receive a stem cell transplant.
This description comes directly from the study's public registry record.
Christian B Gocke, MD PhD · 4109558839 · cgocke2@jhmi.edu
Amanda Stevens, MD · 7869994146 · msteve35@jhmi.edu
Always discuss trial participation with your own doctor first.
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06398457